Literature DB >> 28279376

Trials Testing the Value of Imaging Use in Valve Disease and in Transcatheter Valvular Interventions.

Jonathon Leipsic1, Jeroen J Bax2, John G Webb3, Randolph Martin4, Philipp Blanke3.   

Abstract

The role of imaging in the diagnosis of valvular heart disease is well established through years of investigation and validation. However, the role of imaging in guiding the treatment decision-making for valvular heart disease is less well established, and there is a striking paucity of randomized trial data to help inform these decisions. Given this relative absence of randomized trial data, the present article highlights some of the most important knowledge gaps and defines meaningful opportunities for the field to help advance the care of patients with valvular heart disease in a cost-effective fashion. (The PARTNER 3-Trial: The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3]; NCT02675114; Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TAVR; aortic stenosis; transcatheter mitral valve replacement; valvular heart disease

Mesh:

Year:  2017        PMID: 28279376     DOI: 10.1016/j.jcmg.2016.09.031

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  2 in total

Review 1.  Training and Service Provision in Cardiovascular CT: International Challenges and Solutions.

Authors:  E D Nicol; J Shambrook; E Shaw; J Leipsic; L Shaw
Journal:  Curr Cardiol Rep       Date:  2017-10-18       Impact factor: 2.931

2.  Left ventricular outflow obstruction predicts increase in systolic pressure gradients and blood residence time after transcatheter mitral valve replacement.

Authors:  Adelaide De Vecchi; David Marlevi; David A Nordsletten; Ioannis Ntalas; Jonathon Leipsic; Vinayak Bapat; Ronak Rajani; Steven A Niederer
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.